임상분리균주에 대한 은 나노입자(NANOVER)의 생체외 항균력 시험
In Vitro Antimicrobial Activities of Silver Nanoparticles (NANOVER) against Clinical Isolates
1
조회
0
다운로드
1
인용
0
참고문헌
초록
배경：은은 광범위하고 강력한 항균효과를 가진 것으로 잘 알려져 있으며 다양한 목적으로 의료분야에서 이용되고 있다. 최근 나노입자 크기의 은 입자가 개발되었고 항균력이나 세포독성 면에서 이전의 형태보다 우수한 성질을 가지고 있다. 흔한 임상 병원체에 대해 은 나노입자의 감수성을 연구한 국내 보고가 거의 없어 저자들은 임상분리균주에 대한 NANOVER의 항균력을 조사하였다. 방법：대상 균주에 대한 NANOVER의 최소억제농도(minimum inhibitory concentration, MIC)를 CLSI 기준에 따라 한천희석법으로 구하였다. 임상분리균주는 모두 본원에서 분리된 것으로 Staphylococcus aureus 12주[methicillin-resistant S. aureus (MRSA) 5주, methicillin-susceptible S. aureus (MSSA) 7주], Escherichia coli 14주, Pseudomonas aeruginosa 15주였고 표준균주가 4주(S. aureus ATCC 25923, E. coli ATCC 25922, P. aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212)로 총 45주를 실험하였다. 결과：S. aureus에 대한 MIC는 methicillin 내성 여부에 상관없이 모두 12.5 μg/mL이었고 나머지 균주들도 12.5에서 6.25 μg/mL 이하의 MIC를 보여주었다. 결론：임상분리균주에 대한 NANOVER의 항균력은 강력하고 다른 항균제에 내성을 보이는 균주를 포함하여 광범위함을 알 수 있었다.
Abstract
Background: Silver has extensive and powerful antimicrobial activities and silver-containing materials have been widely used in many medical fields. Recently nanoparticulate silver was developed and it is superior to other types of silver in the antimicrobial activity and cytotoxicity. There have been no data from Korea on its antimicrobial activity, and we evaluated the antimicrobial activity of NANOVER against common clinical isolates. Methods: Minimum inhibitory concentrations (MICs) of NANOVER for clinical isolates were determined using the agar dilution method of Clinical and Laboratory Standard Institute. A total of 45 isolates were tested including 4 reference strains (Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212), 5 strains of methicillin-resistant S. aureus (MRSA), 7 strains of methicillin-sensitive S. aureus (MSSA), 14 strains of E. coli, and 15 strains of P. aeruginosa. Results: The MICs of S. aureus to NANOVER were under 12.5 μg/mL regardless of the methicillin sensitivity or resistance. The other isolates showed the MICs under 12.5 to 6.25 μg/mL. Conclusion: NANOVER has strong and extensive antimicrobial activities to common clinical isolates including those resistant to other antimicrobials.
참고문헌 (19)
- "Pharmacology and clinical use of silver sulfadiazine and related topical antimicrobial agents", 8, pp.45~64 (1977)
- "Antimicrobial activity and action of silver", 31, pp.351~70 (1994)
- "Efficacy of topical silver against fungal burn wound pathogens", 27, pp.344~350 (1999)
- "Antibacterial properties of a silver chloride-coated nylon wound dressing", 28 (1999)
- "Direct confocal microscopy studies of the bacterial colonization in vitro of a silver-coated heart valve sewing cuff", 13, pp.169~167 (2000)
- "Catheter-associated infections in urology:possible use of silver-impregnated catheters and the Erlanger silver catheter", 27, pp.74~77 (1999)
- "In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter", 9, pp.55~70 (1994)
- "Antimicrobial activity of silastic tympanostomy tubes impregnated with silver oxide.", 121, pp.562~565 (1995)
- "Nanocrystalline silver:where the old and familiar meets a new frontier", 13, pp.5~10 (2001)
- "An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement", 25, pp.4383~4391 (2004)
- "Use of catheters with the AgION antimicrobial system in kidney transplant recipients to reduce infection risk", 38, pp.707~710 (2006)
- "Interaction of silver(I) ions with the respiratory chain of Escherichia coli: an electrochemical and scanning electrochemical microscopy study of the antimicrobial mechanism of micromolar Ag+.", 44, pp.13214~13223 (2005)
- "Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria.", 275, pp.177~182 (2004)
- "I: Its antibacterial properties and mechanism of action", 11, pp.125~130 (2002)
- "How safe is silver in wound care?", 13, pp.131~136 (2004)
- "Synthesis and antibacterial properties of silver nanoparticles", 5, pp.244~249 (2005)
- "Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial-thickness burn wounds", 89, pp.953~958 (2006)
- "Comparison of silver-coated dressing (Acticoat) chlorhexidine acetate 0.5% (Bactigrass) and fusidic acid 2% (Fucidin) for topical antibacterial effect in methicillin-resistant staphylococci-contaminated, fullskin thickness rat burn wounds", 31, pp.874~877 (2005)
- "In vitro activity of climbazole,clotrimazole and silver-sulphadiazine against isolates of Malassezia pachydermatis", 44, pp.193~197 (1997)